Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $4.00 price target on Inhibikase Therapeutics Inc (NASDAQ: IKT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE